Charles Schwab Investment Management Inc. Has $3.11 Million Stake in Celcuity Inc. (NASDAQ:CELC)

Charles Schwab Investment Management Inc. boosted its stake in Celcuity Inc. (NASDAQ:CELC) by 7.2% in the fourth quarter, HoldingsChannel reports. The firm owned 237,706 shares of the company’s stock after acquiring an additional 16,035 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Celcuity were worth $3,112,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in Celcuity by 2,083.4% during the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock valued at $673,000 after purchasing an additional 43,044 shares during the period. Geode Capital Management LLC grew its holdings in shares of Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock valued at $9,401,000 after buying an additional 136,518 shares during the period. State Street Corp increased its position in shares of Celcuity by 152.2% in the 3rd quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after buying an additional 668,318 shares in the last quarter. Braidwell LP raised its stake in Celcuity by 71.2% during the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after buying an additional 367,663 shares during the period. Finally, Barclays PLC lifted its holdings in Celcuity by 567.6% during the third quarter. Barclays PLC now owns 53,605 shares of the company’s stock worth $800,000 after acquiring an additional 45,576 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Needham & Company LLC increased their price target on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $30.17.

Celcuity Trading Up 1.0 %

Shares of NASDAQ:CELC opened at $10.54 on Friday. The firm has a market cap of $391.35 million, a price-to-earnings ratio of -4.04 and a beta of 0.65. The company’s fifty day simple moving average is $11.21 and its 200 day simple moving average is $13.01. Celcuity Inc. has a 12 month low of $8.53 and a 12 month high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.